Researchers from the UK have developed a method that allows you to quickly measure the number of T cells in the cancer tumor and on the basis of this predict whether the patient’s patient’s response to immunotherapy will be successful. The article of scientists was published in the journal Nature.
Sequencing of complete exhoma – all gene coding genes – DNA cancer tumors makes it possible to understand how they developed in a patient. However, it has not been able to estimate with it with its help the number of immune cells in the patient’s body. Now, researchers from the University College of London and the Francis Creation Institute developed a method for estimating V (D) J-recombination of T cells – a process, during which those forming antigen receptors are formed. Scientists have discovered an indicator that speaks of the loss of T-receptor excision rings – a sign of ripening of these cells.
The quantitative assessment of this loss is noted by specialists, you can predict the effectiveness of evasion of cancer cells from the recognition of the immune system and the response to cancer immunotherapy as a whole – in particular, it was shown for the adenocarcinoma of the lungs. Especially, scientists believe that their method will help assess the effectiveness of treatment with control points inhibitors – “blocking” proteins, which prevent too much immune response using T-cells.